drugset
drugset / Trial / NCT00516542

Dehydroepiandrosterone (DHEA) and Letrozole in Treating Patients With Metastatic Breast Cancer

NCT00516542 ↗

Phase 1 Terminated 6 enrolled OHSU Knight Cancer Institute National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Androgens can cause the growth of breast cancer cells. Hormone therapy using dehydroepiandrosterone (DHEA) may fight breast cancer by blocking the use of androgen by the tumor cells. Letrozole may stop the adrenal glands from making androgens. Giving DHEA together with letrozole may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of DHEA when given together with letrozole in treating patients with metastatic breast cancer.

Timeline

Start
2007-06
Primary completion
2009-07
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dehydroepiandrosterone Other / unclassified 500 mg Oral
Subject Dehydroepiandrosterone Other / unclassified 5000 mg Oral
Background Letrozole Other / unclassified 2.5 mg Oral

Indications

breast cancer